The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarcevaâ
(OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in
the mouth. The safety of this drug will also be studied, as well as the drug's effect on
different cells in the body.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Astellas Pharma US, Inc. National Cancer Institute (NCI)